Drug Profile
SRX 251
Alternative Names: API 251; SRX251Latest Information Update: 03 Jan 2024
Price :
$50
*
At a glance
- Originator Azevan Pharmaceuticals
- Class Behavioural disorder therapies; Neuropsychotherapeutics
- Mechanism of Action Vasopressin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Aggression
- Discontinued Dysmenorrhoea
Most Recent Events
- 03 Jan 2024 SRX 251 is still in preclinical development (Azevan Pharmaceuticals Pipeline; January 2024)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Aggression in USA (PO)
- 11 Jan 2010 SRX 251 is still in active development